Table 1.
Patient characteristics.
| Characteristics | Unresectable (n = 49) | Completely resected (n = 22) | P |
|---|---|---|---|
| Age | |||
| Mean (SD) | 63.0 (11.4) | 59.1 (6.8) | |
| Range | 30–83 | 47–74 | |
| Sex | 0.22 | ||
| Male | 34 | 12 | |
| Female | 15 | 10 | |
| TNM classification | <0.0001 | ||
| ΙΙ | 0 | 3 | |
| ΙΙΙ | 0 | 13 | |
| IV | 49 | 6 | |
| Primary lesion | 0.19 | ||
| Colon | 19 | 12 | |
| Rectum | 20 | 9 | |
| Other | 10 | 1 | |
| Histology | 0.07 | ||
| Tubular adenocarcinoma | 44 | 19 | |
| Mucinous adenocarcinoma | 1 | 3 | |
| Other | 4 | 0 | |
| Chemotherapy | 0.03 | ||
| mFOLFOX6 | 14 | 12 | |
| FOLFIRI | 9 | 1 | |
| IRIS | 11 | 0 | |
| XELOX | 3 | 4 | |
| Capecitabine | 5 | 1 | |
| Other | 7 | 4 | |
Statistical analysis for single comparisons was performed using the two-tailed χ2 test or Fisher's exact test (expected frequency < 5). Comparisons between two groups were performed with the Mann–Whitney U-test. Staging was classified according the UICC TNM classification of malignant tumors. mFOLFOX6 comprised infusional 5-fluorouracil + l-leucovorin + oxaliplatin, FOLFIRI comprised infusional 5-fluorouracil + l-leucovorin + irinotecan, IRIS consisted of S-1 (an oral prodrug of 5-fluorouracil) + irinotecan, and XELOX consisted of capecitabine + oxaliplatin.